Aim To describe the consecutive pregnancy outcome and treatment in refractory obstetrical antiphospholipid syndrome (APS). Methods Retrospective multicenter open-labelled study from December 2015 to June 2016. We analyzed the outcome of pregnancies in patients with obstetrical APS (Sydney criteria) and previous adverse obstetrical event despite low-dose aspirin and low-molecular weight heparin LMWH (LMWH) conventional treatment who experienced at least one subsequent pregnancy. Results Forty nine patients with median age 27 years (23 â 32) were included from 8 European centers. Obstetrical APS was present in 71%, while 26% had obstetrical and thrombotic APS. Lupus anticoagulant was present in 76% and triple antiphospholipid antibody (APL...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
To summarize the maternal/fetal outcome of pregnancy in antiphospholipid syndrome (APS) patients to ...
Background: The optimal treatment of women with primary antiphospholipid syndrome (APS) is still deb...
Aim To describe the consecutive pregnancy outcome and treatment in refractory obstetrical antiphosph...
To describe the consecutive pregnancy outcome and treatment in refractory obstetrical antiphospholip...
To compare characteristics, pregnancies and treatments during pregnancies of seronegative and seropo...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
To summarize the maternal/fetal outcome of pregnancy in antiphospholipid syndrome (APS) patients to ...
Background: The optimal treatment of women with primary antiphospholipid syndrome (APS) is still deb...
Aim To describe the consecutive pregnancy outcome and treatment in refractory obstetrical antiphosph...
To describe the consecutive pregnancy outcome and treatment in refractory obstetrical antiphospholip...
To compare characteristics, pregnancies and treatments during pregnancies of seronegative and seropo...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
International audienceObjective: To compare characteristics, pregnancies and treatments during pregn...
To summarize the maternal/fetal outcome of pregnancy in antiphospholipid syndrome (APS) patients to ...
Background: The optimal treatment of women with primary antiphospholipid syndrome (APS) is still deb...